NasdaqCM - Nasdaq Real Time Price USD

Aeterna Zentaris Inc. (AEZS)

1.9600

-0.0200

(-1.01%)

At close: April 25 at 4:00 PM EDT

1.9900

0.00

(0.00%)

Pre-Market: 8:00 AM EDT

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate comple

GlobeNewswire 29 days ago

CRPOF

AEZS
-1.01%
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates

AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks 29 days ago

AEZS
-1.01%
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger of equals transaction with Ceapro, Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, March 27, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercia

GlobeNewswire 30 days ago

AEZS
-1.01%
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “Transaction”) at their respective special meetings held today. The specific voting results were as follows: Aeterna shareholders approved the Transaction with the follo

GlobeNewswire last month

AEZS
-1.01%
CRPOF
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed.”ISS states in its Ceapro FOR recommendation that “The arrangement is the result of arm's length negotiations between the parties and carries sound strategic logic.”Aeterna Zentaris and Ceapro securityholders are encouraged to vote well in advance

GlobeNewswire last month

CRPOF

AEZS
-1.01%
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at www.AEZSmerger.comShareholders with questions or who require assistance voting their shares should contact Kingsdale Advisors at 1-866-581-1513 (North American Toll Free) or 416-623-2513 (outside North America – text and call enabled) or contactus@kingsdaleadvisors.com TORONTO, Feb. 15, 2024 (GLOB

GlobeNewswire 2 months ago

CRPOF

AEZS
-1.01%
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today announced that they have entered into a definitive agreement to combine operations in an all-stock merger of equals transaction (the “Transaction”). The combined company is expected to be listed on the Nasdaq Capital Market (“Nasdaq”) and the Toronto Stock Exchange

GlobeNewswire 4 months ago

CRPOF

AEZS
-1.01%
Aeterna Zentaris Reports Third Quarter 2023 Financial Results

- Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmac

GlobeNewswire 5 months ago

AEZS
-1.01%
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate a

GlobeNewswire 6 months ago

AEZS
-1.01%
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually. Dr. P

GlobeNewswire 7 months ago

AEZS
-1.01%
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks 8 months ago

AEZS
-1.01%
Aeterna Zentaris Reports Second Quarter 2023 Financial Results

Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and o

GlobeNewswire 8 months ago

AEZS
-1.01%
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

Highlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards first in human studiesStrong financial position with cash projected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, July 13, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a dive

GlobeNewswire 9 months ago

AEZS
-1.01%
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Thursday, July 13th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer and Eckhard Guenther, PhD, Managing Director and SVP, Business Development of Aeterna Zentaris, will p

GlobeNewswire 9 months ago

AEZS
-1.01%
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all items of business were approved at its virtual Annual General and Special Meeting of Shareholders (the "AGM") held today. Results of the AGM At the AGM, all items of business were approved. The individuals no

GlobeNewswire 10 months ago

AEZS
-1.01%
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders

TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that its Virtual Annual General and Special Meeting of Shareholders (the “AGM”) will be held on June 14, 2023, at 10:00 a.m. (ET). The platform for the virtual AGM will provide shareholders the ability to listen to the

GlobeNewswire 11 months ago

AEZS
-1.01%
Aeterna Zentaris Reports First Quarter 2023 Financial Results

– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and commercialization partners for Macrilen® (macimorelin) in the U.S. and other territories not currently partnered TORONTO, ONTARIO, May 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializ

GlobeNewswire 11 months ago

AEZS
-1.01%

Performance Overview

Return	AEZS	S&P/TSX Composite index
YTD	+5.38%	+4.42%
1-Year	-38.75%	+5.85%
3-Year	-91.66%	+14.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aeterna Zentaris Inc. (AEZS)

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

Aeterna Zentaris Reports Third Quarter 2023 Financial Results

Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates

Aeterna Zentaris Reports Second Quarter 2023 Financial Results

Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders

Aeterna Zentaris Reports First Quarter 2023 Financial Results

Performance Overview